2. Chang S.S., Gaudin P.B., Reuter V.E., Heston W.D.W. Prostate-specific membrane antigen: Present and future applications. Urology. 2000;55(5):622–629. Doi: 10.1016/s0090-4295(99)00600-7.

3. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;16(3):481–488. Doi: 10.1093/annonc/mdi098. PMID: 15718248.

4. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). M.: MNIOI im. P.A. Gertsen – filial FGBU «NMIRTS» Minzdrava Rossii, 2017;12–36 p. Russian (Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ НМИРЦ Минздрава России, 2017;12–36 с.).

5. Veliev E.I., Sokolov Ye.A., Loran O.B. Improvement of recurrence-free survival after radical prostatectomy in locally advanced prostate cancer, depending on the duration of surgery. Onkourologiya. 2016;1(12):69–73. Doi.10.17650/1726-9776-2016-12-1-69-73. Russian (Велиев Е.И., Соколов Е.А., Лоран О.Б. Улучшение рецидивной выживаемости после радикальной простатэктомии при местно-распространенном раке предстательной железы в зависимости от срока оперативного вмешательства. Онкоурология. 2016;1(12):69–73. Doi.10.17650/1726-9776-2016-12-1-69-73).

6. Pushkar D.Yu. Radical prostatectomy. M.: MEDpress-inform. 2002;168 p. Russian (Пушкарь Д.Ю. Радикальная простатэктомия. М.: МЕДпресс-информ. 2002;168 с.).

7. Abdollah F., Sun M., Schmitges J., et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J. Urol. 2012;188:73–83. Doi: 10.1016/j.juro.2012.03.005.

8. Augustin H., Hammerer P., Graefen M. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur. Urol. 2003;43(2):113–18. Doi: 10.1016/s0302-2838(02)00495-5.

9. Petrov S.B., Veliev E.I. Surgical treatment of localized prostate cancer. Prakt. onkologiya. SPb.: RMZH. 2001;2(6):50–52. Russian (Петров С.Б., Велиев Е.И. Хирургическое лечение локализованных форм рака предстательной железы. Практ. онкология. СПб.: РМЖ. 2001;2(6):50–52).

10. Isbarn H., Wanner M., Salomon G., et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2010;106(1):37–43. Doi: 10.1111/j.1464-410X.2009.09134.x.

11. Porter C.R., Kodama K., Gibbons R.P., et. al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. Urol. 2006;176(2):569–574. Doi: 10.1016/j.juro.2006.03.094.

12. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et. al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–1996. Doi: 10.1200/JCO.2005.05.2530.

13. Pereverzev A.C., Kogan M.I. Prostate cancer. Khar'kov: Fakt. 2004;231 p. Russian (Переверзев A.C., Коган М.И. Рак простаты. Харьков: Факт. 2004;231 с.).

14. Solovov V.A., Orlov A.Ye., Vozdvizhenskiy M.O. et al. High intensity focused ultrasound ablation (HIFU) of prostate cancer in 976 patients: 7-year results. Izvestiya Samarskogo nauchnogo tsentra Rossiyskoy akademii nauk. 2015;2(3):682–85. Russian (Соловов В.А., Орлов А.Е., Воздвиженский М.О. и др. Высокоинтенсивная фокусированная ультразвуковая аблация (HIFU) рака предстательной железы у 976 пациентов: 7-летние результаты. Известия Самарского научного центра Российской академии наук. 2015;2(3):682–685).

15. Nguyen D.P., Giannarini G., Seailer R. et al. Local recurrence after retropubic radical prostatectomy for prostate cancer does not exclusively occur at the anastomotic site. BJU Int. 2013;112(4):E243–49. Doi: 10.1111/j.1464-410X.2012.11506.x.

16. Chernyayev V.A., Matveyev V.B., Volkova M.I., et al. Prognosis factors for biochemical recurrence of localized and locally advanced prostate cancer after radical prostatectomy. Onkourologiya. 2012;4:58–64. Doi: 10.17650/1726-9776-2012-8-4-58-64. Russian (Черняев В.А., Матвеев В.Б., Волкова М.И., и др. Факторы прогноза биохимического рецидива локализованного и местно-распространенного рака простаты после радикальной простатэктомии. Онкоурология. 2012;4:58–64. Doi: 10.17650/1726-9776-2012-8-4-58-64).

17. Babaian R.J., Troncoso P., Bhadkamkar V.A., Johnston D.A. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91(8):1414–1422.

18. Gorban' N.A., Kapyakin A.O. Prognosis factors for prostate cancer. Onkourologiya. 2010;4:47–54. Doi. 10.17650/1726-9776-2010-6-4-47-53. Russian (Горбань Н.А., Капякин А.О. Факторы прогноза при раке предстательной железы. Онкоурология. 2010;4:47–54. Doi. 10.17650/1726-9776-2010-6-4-47-53).

19. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005;29(9):1228–1242. Doi: 10.1097/01.pas.0000173646.99337.b1.

20. Carvalhal G.F., Humphrey P.A., Thorson P., et. all. Visuale estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000;89(6):1308–1314. Doi. 10.1002/1097-0142(20000915)89:6<1308::aid-cncr16>3.0.co;2-3.

21. Blute M.L., Bergstralh E.J. el al. Use of Gleason score, prostatespecific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001;165:119–125. Doi: 10.1097/00005392-200101000-00030.

22. Gritskevich A.A., Medvedev V.L., Kostin A.A., Rusakov I.G. Prognostic factors of survival in patients with prostate cancer. M.: Eksperimental'naya i klinicheskaya urologiya. 2017;4:12–19 . Russian (Грицкевич А.А., Медведев В.Л., Костин А.А., Русаков И.Г. Прогностические факторы выживаемости больных при раке предстательной железы. М.: Экспериментальная и клиническая урология. 2017;4:12–19).

23. Lachinov E.L. Diagnosis and prediction of local recurrence of prostate cancer after radical prostatectomy using magnetic resonance imaging. Avtoreferat dissertatsiya kandidata med. nauk. M. 2014; 23 s. Russian (Лачинов Э.Л. Диагностика и прогнозирование местного рецидива рака простаты после радикальной простатэктомии с использованием магнито-резонансной томографии. Автореферат диссертация кандидата мед. наук. М. 2014; 23 с.).

24. McNeal J.E., Villers A.A., Redwine E., et. all. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am. J. Surg. Pathol. 1990;14(3):240–247. Doi: 10.1097/00000478-199003000-00005.

25. Greene D.R., Wheeler T.M., Egawa S., et. all. A Сomparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 1991;146(4):1069–1076. Doi: 10.1016/s0022-5347(17)38003-5.

26. Gilbert S.M., Cavallo C.B., Kahane H., et. all. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549–553. Doi: 10.1016/j.urology.2004.10.064.

27. Shatov A.V., Berezutskiy M.V., Strukov M.V. The use of low-field magnetic resonance imaging in the complex diagnostics of prostatic diseases. Urol. i nefrol. 1996;(5):33–37. Russian (Шатов А.В., Березуцкий М.В., Струков М.В. Применение низкопольной магнитно-резонансной томографии в комплексе лучевой диагностики заболеваний предстательной железы. Урол. и нефрол. 1996;(5):33–37).

28. Catalona W.J., Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate- term results. J. Urol. 1998;160(6):2428–2434. Doi: 10.1097/00005392-199812020-00012.

29. Ito K., Nakashima J., Mukai M., et. all. Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol. Int. 2003;70(4):297–302. Doi: 10.1159/000070139.

30. Wheeler T.M., Dillioglugil O., Rattan M.W., et. all. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage Tl-2 prostate cancer. Hum. Pathol. 1998;29(8):856–862. Doi: 10.1016/s0046-8177(98)90457-9.

31. Veliev E.I. Optimization of surgical treatment of patients with localized prostate cancer. Avtoreferat dissertatsiya doktora med. nauk. SPb. 2003;40 s. Russian (Велиев Е.И. Оптимизация хирургического лечения больных локализованным раком предстательной железы. Автореферат диссертация доктора мед. наук. СПб. 2003;40 с.).

32. D’Amico A.V., Whittington R., Malkowicz S.B., Schultz D. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score <or=7. 2000;88(9):2110–2115. Doi: 10.1002/(sici)1097-0142(20000501)88:9<2110::aid-cncr17>3.0.co;2-e.

33. Epstein J.I. Surgical margins in patients with carcinoma of the prostate. AUA Update Series. 1994;8(7):53–59.

34. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;7(71):3582–3593. Doi: 10.1002/1097-0142(19930601)71:11<3582::aid-cncr2820711120>3.0.co;2-y

35. Blute M.L., Bergstralh E.J., el al. Use of Gleason score, prostatespecific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001;165:119–125. Doi: 10.1097/00005392-200101000-00030.

36. Ikonen S., Karkkainen P., Kivisaari L., et al. Magnetic resonance imaging of prostatic cancer: does detection vary between high and low gleason score tumors? The Prostate. 2000;43(1):43–48. Doi: 10.1002/(sici)1097-0045(20000401)43:1<43::aid-pros6>3.0.co;2-s.

37. Salomon L., Anastasiadis A.G., Antiphon P., et al. Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol. Int. 2003;70(4):491–496. Doi: 10.1159/000070138.

38. Gleason D.F. Histologic grading of prostate cancer – a perspective. Hum. Pathol. 1992;23(3):273–279. Doi: 10.1016/0046-8177(92)90108-f.

39. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005;29(9):1228–1242. Doi: 10.1097/01.pas.0000173646.99337.b1.

40. Smith J.A. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases at Montsouris Institute. Urol. Oncol. 2003;21(6):480–481.

41. Villers A.A., McNeal J.E., Redwine E., et. all. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J. Urol. 1989;142(3):763–768. Doi: 10.1016/s0022-5347(17)38881-x.

42. Pushkar D.Yu., Bormotin A.V. Changes of the prostate cancer stage after radical prostatectomy. M.: Urologiia, 2003; (3): 11-14 p. Russian (Пушкарь Д.Ю., Бормотин А.В. Уточнение стадии рака предстательной железы после радикальной простатэктомии. М.: Урология 2003;(3):11–14).

43. Maru N., Ohori M., Kattan M.W., et. all. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum. Pathol. 2001;32(8):828–833. Doi: 10.1053/hupa.2001.26456.

44. Katz B., Srougi M., Dall’oglio M., et. all. Perineural invasion detection in prostate biopsy is related to recurrence-free survival in patients submitted to radical prostatectomy. Urologic Oncology. 2013;31(2):175–179. Doi: 10.1016/j.urolonc.2010.11.008.

45. Herman C.M., Wilcox G.E., Kattan M.W., et. all. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am. J. Surg. Pathol. 2000;24(6):8598–8563. Doi: 10.1097/00000478-200006000-00012.

46. De la Taille A., Rubin M.A., Buttyan R., et. all. Is microvascular invasion on radical prostatectomy specimen a useful predictor of PSA recurrence for prostate cancer patients? Eur. Urol. 2000;2:134–136. Doi: 10.1159/000020256.

47. Yee D.S., Shariat S.F., Lowrance W.T., et. all. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2011;108(4):502–507. Doi: 10.1111/j.1464-410X.2010.09848.x.

48. Roberts W.W., Bergstralh E.J., Blute M.L., et. all. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. 2001;57(6):1033–1037. Doi: 10.1016/s0090-4295(01)00978-5.

49. Baydar D.E., Baseskioglu B., Ozen H., Geyik P.O. Prognostic significance of lymphovascular invasion in clinically localized prostate cancer after radical prostatectomy. Scientific World Journal. 2008;8:303–312. Doi: 10.1100/tsw.2008.49.

50. Zhou M., Hayasaka S., Taylor J.M., et. all. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. J. Urol. 2001;166(6):2193–2198.

51. Djavan B., Moul J.W., Zlotta A., et. all. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43(l):12–27. Doi: 10.1016/s0302-2838(02)00505-5.

52. Rouviere O., Vitry T., Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur. Radiol. 2010;20(5):1254–1266. Doi: 10.1007/s00330-009-1647-4.

53. Amling C.L., Bergstralh E.J., Blute M.L., et. all. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 2001;165(4):1146–1151.

54. Grossfeld G.D., Latini D.M., Lubeck D.P., et. all. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. Hi. Urol. 2003;169(1):157–63. Doi: 10.1016/s0090-4295(01)01658-2.

55. Kausik S.J., Blute M.L., Sebo T.J., et. all. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002;95(6):1–12. Doi: 10.1002/cncr.10871.

56. Koppie T.M., Grossfeld G.D., Nudell D.M., et. all. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J. Urol. 2001;166(1)111–115.

57. Cronin A.M., Godoy G., Vickers A.J. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. Urol. 2010;183(3):984–989. Doi: 10.1016/j.juro.2009.11.027.

58. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003;169(2):517–25. Doi: 10.1097/01.ju.0000045749.90353.c7.

59. Briganti A., Karnes R.J., Joniau S., et al. Prediction of outcome following early salvage radiotherapy among patientswith biochemicalrecurrence after radical prostatectomy. Eur Urol. 2014;66(3):479–486. Doi: 10.1016/j.eururo.2013.11.045.

60. Brockman J.A., Alanee S., Vickers A.J., et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015;67(6):1160–1167. Doi: 10.1016/j.eururo.2014.09.019.

61. Gervas P.A., Litvyakov N.V., Popova N.O., Dobrodeyev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanas'yev S.G., Gol'dberg V.E., Cherdyntseva N.V. Problems and prospects of improving molecular genetic diagnostics for choosing targeted drugs in oncology. Sibirskiy onkologicheskiy zhurnal. 2014; (2): 46–55. Russian (Гервас П.А., Литвяков Н.В., Попова Н.О., и др. Проблемы и перспективы совершенствования молекулярно-генетической диагностики для назначения таргетных препаратов в онкологии. Сибирский онкологический журнал. 2014;2:46–55).

62. Vtorushin S.V., Bezgodova N.V., Pleshkunov A.A. Molecular and biological prognostic factors for prostate cancer. Sibirskiy onkologicheskiy zhurnal. 2017;16(1):82–90. Russian (Вторушин С.В., Безгодова Н.В., Плешкунов А.А. Молекулярно-биологические факторы прогноза при раке предстательной железы. Сибирский онкологический журнал. 2017;16(1):82–90. Doi. 10.21294/1814-4861-2017-16-1-82-90).

63. Zincke H., Osterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850–1857. Doi: 10.1016/s0022-5347(17)32399-6.